Trial Profile

A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 03 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aliskiren (Primary) ; Amlodipine; Hydrochlorothiazide
Indications Cardiovascular disorders; Hypertension
Focus Registrational; Therapeutic Use
Acronyms APOLLO
Sponsors Novartis

Most Recent Events

31 Jul 2022 This trial has been completed in Germany (End Date: 02 Nov 2012), according to European Clinical Trials Database record.
26 Jun 2019 This trial has been completed in Hungary, according to European Clinical Trials Database
19 Jul 2013 Status changed from active, no longer recruiting to discontinued.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com